Skip to main content

Prelude Therapeutics Inc 8-K, filed Nov 16, 2026

Prelude Therapeutics Inc (PRLD)

8-K 2026-11-16 For: 2026-11-16
View Original
Added on November 16, 2026

About this 8-K

Prelude Therapeutics Inc filed this 8-K on November 16, 2026.

Prelude Therapeutics began Phase 1 enrollment for PRT13722 in HR+/HER2- breast cancer, expects proof-of-concept data in the 2nd half of 2027, and expects cash to fund operations into the second quarter of 2028. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits